Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens.

Due to the model-inherent highly variable time to tumor progression in all experimental groups, these data did not reach statistical significance.

also in 111,027 other papers

Mice treated with the combination showed a trend toward a delayed onset of accelerated tumor growth and longer survival ( Supplementary Figure 21 B, C, and D ).

also in 53,322 other papers

The combination of niraparib, the second most potent PARP-trapping agent, 47 with the topoisomerase inhibitor topotecan demonstrated a clear trend towards synergistic interactions for the 2 DHG-H3G34R_ATRX models (VBT347, VBT375; Figure 3B , Supplementary Figure 11, 12A ), as well as VBT125 ( Figure 3C , Supplementary Figure 11 , 12A ), whereas antagonistic effects were observed in all other models ( Figure 3C , Supplementary Figure 11 , 12A ).

also in 19,460 other papers